JAZZ News and Press, Jazz Pharmaceuticals plc From 10/11/20

Praxis Precision Medicines has filed proposed terms for its U.S. IPO. The firm is developing treatments for various central nervous system and other disorders. PRAX has demonstrated positive early efficacy results, so for life science investors, the IPO is worth a close look. ...

Jazz Pharmaceuticals (JAZZ) up 4% in premarket, on top-line results from the Phase 3 withdrawal study that is evaluating Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution in adult patients with idiopathic hypersomnia.The study included 115 patients with primar...

Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Adult Patients with Idiopathic Hypersomnia Clinically meaningful and highly statistically significant results for pr...

Kronos Bio has filed proposed terms for a $175 million U.S. IPO. The firm is advancing a pipeline of treatment candidates for acute myeloid leukemia [AML] and solid tumors. KRON has shown intriguing early trial results and has a significant collaboration relationship with Gilead S...

Biotech companies working on vaccines or treatments for COVID-19 have been grabbing much attention from pundits and analysts. But for investors, it's important to remember that there are companies within this industry that are not directly involved in the fight against the coronavirus -...

DUBLIN , Sept. 17, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the launch of Find the Right Fit ( FindTheRightFit-sAML.com ), a U.S. patient education program developed in consultation with the Myelodysplastic Syndromes (MDS) Foundation, Inc. and the Cance...

Jazz Pharmaceuticals is proud to support the American Heart Association's sleep health educational content   Research demonstrates that disrupted sleep and sleep disorders are associated with a higher risk of cardiovascular and cardiometabolic diseases, including obesity, diab...

Albireo reports positive data from Phase 3 trial Albireo Pharma, Inc. (ALBO) reported positive top-line data from PEDFIC 1 trial for odevixibat. The study met both its primary endpoints. The drug candidate is a highly potent, non-systemic ileal bile acid transport inhibitor. It is being ...

Jazz Pharmaceuticals (NASDAQ: JAZZ ) has signed a research collaboration agreement with Redx Pharma to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase (MAPK) pathway. More news on: Jazz Pharmaceuticals plc, Healthcare stocks news, Read more ......

Research Collaboration on Two Targeted Oncology Programs in the Ras/Raf/MAP Kinase Pathway Redx to Receive $10 Million Upfront and $10 Million in Year 2 with up to $400 Million in Further Milestone Payments Plus Tiered Royalties on any Future Net Product Sales DUBLIN , Sept....